CDC25C and lung adenocarcinoma: In addition, CDC25C is upregulated in lung adenocarcinoma (LUAD), and its high expression is significantly associated with immune cell infiltration and immune-related characteristics in the tumor microenvironment, as well as shortened progression-free survival in LUAD patients receiving nivolumab treatment, indicating a correlation between CDC25C and immunotherapeutic efficacy as well as the tumor immune microenvironment (40).